Navigation Links
KalVista Pharmaceuticals and JDRF Form Research Partnership Focused on Novel Approach for Treating Diabetic Eye Disease
Date:1/9/2012

at the Joslin Diabetes Center on validating plasma kallikrein as a potential therapeutic target for diabetic macular edema underscores JDRF's commitment to developing innovative approaches to prevent and treat this condition to save vision before it deteriorates," said Aaron Kowalski, Ph.D., assistant vice president of Treatment Therapies for JDRF.

KalVista's candidate will be selected from a series of novel small molecule plasma kallikrein inhibitors, which are advancing through pre-clinical development for the treatment of DME by delivery via intravitreal (IVT) injection into the eye. The pre-clinical studies being co-funded by JDRF will test whether administration of plasma kallikrein inhibitors by injection are likely to be safe and effective in improving symptoms of DME as well as in preserving visual acuity and slowing disease progression.

"JDRF is the leading global organization focused on research into diabetes and its complications and we are delighted it has recognized the potential of our novel approach to treating diabetic macular edema based on plasma kallikrein inhibitors," said Andrew Crockett, KalVista's CEO. "This is an exciting collaboration and we look forward to the added expertise they will contribute to the development of our lead programme."

"JDRF's goal is to have the greatest and fastest positive impact on individuals with type 1 diabetes, which is why we are working to accelerate the translation of novel discoveries in the lab, through clinical evaluation of safety and efficacy, and into commercial development," added Kowalski. "What makes our collaboration with KalVista so exciting is that we are gradually seeing this novel therapy, which could represent a whole new approach to treating DME, move from basic research discovery into a potential commercially viable drug with the help of JDRF funding."  

Notes to Editors

About diabetic eye disease and current available treatments

D
'/>"/>

SOURCE JDRF
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema
2. Questcor Pharmaceuticals Reports Strong Finish to 2011
3. Valeant Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
4. Radient Pharmaceuticals Announces New Advertisement for Oncology Publications
5. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
6. Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine
7. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
8. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
9. Acella Pharmaceuticals, LLC Announces Its Acquisition of the PRENATE® Family of Trademarks and Associated Intellectual Property
10. Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
11. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
(Date:1/23/2015)... Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange ... shareholders detailing why a "YES" vote to increase the number ... As we reflect upon the 2014 fiscal year that ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... BENICIA, Calif., Jan. 22 AcroMetrix, a global ... diagnostics,announced today that it will extend its contract ... December 31st of 2009. Following,the previous agreement from ... as a recommended provider of quality control materials,for ...
... Protalix,BioTherapeutics, Inc. (Amex: PLX ), today announced ... an animal study conducted as part of its,Acetylcholinesterase ... under the agreement the Company entered into,with the ... of the Hebrew University of Jerusalem, Israel, and ...
Cached Medicine Technology:AcroMetrix Renews Contract With Group Services for America's Blood Centers 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 3
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce ... Services at North Carolina State’s College of Veterinary Medicine ... Award for Distinguished Volunteer Service—the organization’s highest award. ... of volunteer experts to direct its work to improve ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... NEW YORK, June 24 According to the ... from diabetes,asthma and other chronic conditions. The medical care ... the nation,s $2 trillion medical care,costs. And as the ... its medical bills are expected to spiral further out ...
... a latency period of 10-50,years, and with millions of ... of this life ending disease continue,to disrupt families and ... leadership, members of Congress and three guest speakers,who will ... The press conference will be held on the ...
... to Reduce ... Impact of Diagnosed Health Conditions, LAGUNA HILLS, Calif., ... tasty, satisfying foods that help people prevent and,manage Diabetes ... snack bars in over 200 Southern California Ralph,s,grocery stores. ...
... 2008) The American Academy of Cosmetic Surgery has released ... opinions on medical spas. Findings revealed that millennials, those ... these facilities. Yet half of those women are compromising ... , Women ages 18-34 were more than three times as ...
... Brompton and Harefield NHS Trust,s Leadership Role in the Treatment ... ... Stereotaxis, Inc. (Nasdaq:,STXS) announced that British Prime Minister Gordon Brown presided ... lab at,Royal Brompton Hospital in London. The new lab features Stereotaxis ...
... (NYSE:,HRC) today announced the signing of a distribution ... agreement will enhance selling,efforts for Hill-Rom,s product The ... care facilities within the United States., "We ... said Kim,Dennis, group vice president, Post Acute Care ...
Cached Medicine News:Health News:Healthcare Experts Discuss Current and Future Challenges of Chronic Care on NewTalk 2Health News:Healthcare Experts Discuss Current and Future Challenges of Chronic Care on NewTalk 3Health News:Faces of Mesothelioma; Meso Foundation Press Conference with Families and Patients 2Health News:Heart Disease and Diabetes Finally Meet Their Match With Delicious New Snack Bars From WatchDog Nutrition(TM) 2Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 2Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 3Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 2Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 3Health News:Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: